alexa HIPEC For Peritoneal Malignancies
ISSN: 2161-0932

Gynecology & Obstetrics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd Annual Conference on Gynecologic Oncology & Preventive Oncology
July 20-21, 2017 Chicago, USA

Aaron H Chevinsky
University of Wisconsin Madison School of Medicine and Public Health, USA
Keynote: Gynecol Obstet (Sunnyvale)
DOI: 10.4172/2161-0932-C1-014
Abstract
The use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) for the treatment of peritoneal based malignancies has been ongoing in the Unites States and around the globe for well over 20 years. This procedure, which combines debulking of all visible cancer, often with peritonectomy, bowel resection, splenectomy and removal of other intra-abdominal organs with the infusion of chemotherapy heated to 42 degrees centigrade has been very effective in treating several malignancies which tend to involve the peritoneal surfaces, but has not metastasized or invaded deeply into other organs. The most commonly treated malignancies include pseudomyxoma peritonei, appendiceal, gastric, colorectal cancer, ovarian and primary peritoneal cancer, as well as peritoneal mesothelioma and recurrent sarcomas. It is estimated that as many as 50,000 patients a year in the United States may be candidates for a HIPEC procedure. The majority of the cases have used mitomycin C as the chemotherapy of choice, others have used platinum (oxaliplatin, cisplatin and carboplatin) based agents. Most patients with carcinomatosis will die within one year of diagnosis if untreated and with HIPEC (depending on the initial tumor site) may have as much as a 60-70% five-year survival. In most patients their ascites (which is present in over half the patients) will be controlled and their quality of life will be improved. Studies are ongoing to evaluate the effectiveness of HIPEC in high risk cancers, prone to carcinomatosis, in the adjuvant setting after resection. In gynecologic malignancies, HIPEC has been primarily used in recurrent ovarian cancer, where it has been shown to improve survival and reduce recurrence. Post-operative complications include ileus, respiratory compromise, fluid retention and complications related to chemotherapy absorption (such as pancytopenia). A new HIPEC program was started at Aurora St. Luke’s Medical Center in Milwaukee, Wisconsin in September of 2016. To date we have attempted HIPEC on 10 patients, and have been successful in 9 (in one patient the disease was too extensive for effective debulking). The diagnoses included appendiceal cancer, primary peritoneal cancer, granulosa cell ovarian cancer and colorectal cancer. Our protocol for the evaluation of these complex patients, highlighted the need for multidisciplinary management, the integration of intravenous and intraperitoneal chemotherapy, and the intra-operative and post-operative management will be discussed in detail along with suggestions on how to initiate a HIPEC program at the institution.
Biography

Aaron H Chevinsky is the Director of Surgical Oncology at Aurora Health Care in Wisconsin, USA. He has lectured nationally and internationally and has published on many aspects of cancer care. He has attended medical school and completed his Surgical Residency in New York and completed a Surgical Oncology Fellowship at Ohio State. He has been named to the Top Docs list and has won awards for the development of multidisciplinary cancer care programs. He has also appeared on TV and radio to raise awareness and promote cancer screening he remains committed to providing the best cancer care to the patients he treats.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

g[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords